# Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

> **NCT01544491** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 106 (actual)

## Conditions studied

- Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant

## Interventions

- **DRUG:** RAD001
- **DRUG:** MMF

## Key facts

- **NCT ID:** NCT01544491
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-17
- **Primary completion:** 2016-10-03
- **Final completion:** 2018-09-24
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01544491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01544491, "Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01544491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*